Mickael Guedj
Overview
Explore the profile of Mickael Guedj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Desvaux E, Hamon A, Hubert S, Boudjeniba C, Chassagnol B, Swindle J, et al.
PLoS One
. 2021 Jul;
16(7):e0254374.
PMID: 34293006
While establishing worldwide collective immunity with anti SARS-CoV-2 vaccines, COVID-19 remains a major health issue with dramatic ensuing economic consequences. In the transition, repurposing existing drugs remains the fastest cost-effective...
12.
A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome
Soret P, Le Dantec C, Desvaux E, Foulquier N, Chassagnol B, Hubert S, et al.
Nat Commun
. 2021 Jun;
12(1):3523.
PMID: 34112769
There is currently no approved treatment for primary Sjögren's syndrome, a disease that primarily affects adult women. The difficulty in developing effective therapies is -in part- because of the heterogeneity...
13.
Luo Q, Chen Q, Wang W, Desrivieres S, Quinlan E, Jia T, et al.
JAMA Psychiatry
. 2019 Jan;
76(4):435-445.
PMID: 30649180
Importance: Deviation from normal adolescent brain development precedes manifestations of many major psychiatric symptoms. Such altered developmental trajectories in adolescents may be linked to genetic risk for psychopathology. Objective: To...
14.
Wang W, Guedj M, Bertrand V, Foucquier J, Jouve E, Commenges D, et al.
PLoS One
. 2017 Jan;
12(1):e0169878.
PMID: 28095456
The Charcot-Marie-Tooth Neuropathy Score (CMTNS) was developed as a main efficacy endpoint for application in clinical trials of Charcot-Marie-Tooth disease type 1A (CMT1A). However, the sensitivity of the CMTNS for...
15.
Attarian S, Vallat J, Magy L, Funalot B, Gonnaud P, Lacour A, et al.
Orphanet J Rare Dis
. 2016 Jul;
11(1):92.
PMID: 27387831
No abstract available.
16.
Hajj R, Milet A, Toulorge D, Cholet N, Laffaire J, Foucquier J, et al.
Sci Rep
. 2015 Nov;
5:16084.
PMID: 26542636
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic nigrostriatal neurons but which involves the loss of additional neurotransmitter pathways. Mono- or polytherapeutic interventions in...
17.
Wang W, Mandel J, Bouaziz J, Commenges D, Nabirotchkine S, Chumakov I, et al.
PLoS One
. 2015 Sep;
10(9):e0138223.
PMID: 26379234
Results from Genome-Wide Association Studies (GWAS) have shown that the genetic basis of complex traits often include many genetic variants with small to moderate effects whose identification remains a challenging...
18.
Foucquier J, Guedj M
Pharmacol Res Perspect
. 2015 Jul;
3(3):e00149.
PMID: 26171228
Combination therapies exploit the chances for better efficacy, decreased toxicity, and reduced development of drug resistance and owing to these advantages, have become a standard for the treatment of several...
19.
Mandel J, Bertrand V, Lehert P, Attarian S, Magy L, Micallef J, et al.
Orphanet J Rare Dis
. 2015 Jun;
10:74.
PMID: 26070802
CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression...
20.
Chumakov I, Nabirotchkin S, Cholet N, Milet A, Boucard A, Toulorge D, et al.
Sci Rep
. 2015 Jan;
5:7608.
PMID: 25566747
Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational therapy that might prevent...